Ketamine Therapy in Missouri

Ketamine therapy in Missouri operates within a framework established by both federal and state oversight. At the federal level, ketamine is classified as a Schedule III controlled substance under the Controlled Substances Act, meaning it has accepted medical uses but also carries potential for abuse. Clinicians who administer or prescribe ketamine must hold a valid DEA registration, and all dispensing must comply with federal recordkeeping and storage requirements. Missouri state law aligns with these federal standards, and the Missouri State Board of Pharmacy oversees the handling, compounding, and dispensing of controlled substances within the state, while the Missouri Division of Professional Registration regulates the licensing of healthcare practitioners who provide ketamine infusions.

In Missouri, ketamine infusions for conditions such as treatment-resistant depression, PTSD, anxiety, and chronic pain are typically administered by or under the direct supervision of a licensed physician, anesthesiologist, or nurse anesthetist. Because ketamine is not yet FDA-approved for most psychiatric indications — with the exception of esketamine (Spravato), which is approved for treatment-resistant depression and must be administered in a certified healthcare setting — most IV ketamine treatments are offered as off-label use. Clinics must ensure that patients provide informed consent acknowledging the off-label nature of the treatment, and practitioners are expected to adhere to evolving clinical guidelines published by organizations such as the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3).

Missouri does not currently have a dedicated state-specific regulatory framework exclusively governing ketamine clinics, meaning oversight is distributed across multiple licensing bodies. Practitioners and clinics must comply with the following general requirements:

• Valid state medical or nursing licensure in good standing with the appropriate Missouri licensing board
• DEA Schedule III controlled substance registration for prescribing and administering ketamine
• Compliance with Missouri's Prescription Drug Monitoring Program (PDMP), known as MOLST (Missouri Opioid Summary Tool) or the broader Missouri PDMP system, for tracking controlled substance prescriptions
• Adherence to proper compounding standards if using compounded ketamine preparations, as governed by the Missouri State Board of Pharmacy
• Maintenance of appropriate malpractice insurance and facility safety standards

Prospective patients seeking ketamine therapy in Missouri are encouraged to verify that their chosen provider holds current, unrestricted licensure and DEA registration. The regulatory landscape for ketamine therapy continues to evolve nationally, and Missouri practitioners are increasingly expected to follow best practice guidelines that include thorough psychiatric and medical screening, standardized dosing protocols, and appropriate follow-up care. Patients should feel empowered to ask providers about their credentials, clinical protocols, and how they stay current with emerging standards in the field.